NCT01876446View on ClinicalTrials.gov

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 29, 2013

Primary Completion Date

July 18, 2017

Study Completion Date

February 24, 2020

Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pegylated Irinotecan

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

14621

Rochester General Hospital, Rochester

14625

Linden Oaks Medical Campus, Rochester

Sponsors

Collaborators (1)

Nektar Therapeutics
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Nektar Therapeutics

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01876446 - Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter